BioWorld

April 30, 2008

View Archived Issues

Second Strike on Rituxan as it Fails in Lupus Trial

Still reeling from a negative study of Rituxan in multiple sclerosis patients, Genentech Inc. and Biogen Idec Inc. reported more unfavorable data Tuesday from a Phase II/III study of the drug in lupus patients. (BioWorld Today) Read More

Constellation's Series A Adds $32M for Epigenetics Platform

Read More

Paper Stirs Science Debate Over Tumor Angiogenesis

Read More

Panel Debates Knotty Challenges Facing Follow-on Biologics

Read More

Other News To Note

Read More

Clinic Roundup

Read More